CN112057590A - Chinese medicinal preparation for treating hepatic fibrosis and preparation method thereof - Google Patents
Chinese medicinal preparation for treating hepatic fibrosis and preparation method thereof Download PDFInfo
- Publication number
- CN112057590A CN112057590A CN202011142360.7A CN202011142360A CN112057590A CN 112057590 A CN112057590 A CN 112057590A CN 202011142360 A CN202011142360 A CN 202011142360A CN 112057590 A CN112057590 A CN 112057590A
- Authority
- CN
- China
- Prior art keywords
- parts
- hepatic fibrosis
- preparation
- blood
- treating hepatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 55
- 206010019668 Hepatic fibrosis Diseases 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 claims abstract description 54
- 239000002994 raw material Substances 0.000 claims abstract description 23
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000013535 Dianthus superbus Nutrition 0.000 claims abstract description 19
- 244000183914 Dianthus superbus Species 0.000 claims abstract description 19
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 18
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 18
- 240000004980 Rheum officinale Species 0.000 claims abstract description 17
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 17
- 235000006545 Ziziphus mauritiana Nutrition 0.000 claims abstract description 17
- 244000126002 Ziziphus vulgaris Species 0.000 claims abstract description 17
- 235000008529 Ziziphus vulgaris Nutrition 0.000 claims abstract description 17
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 17
- 235000011477 liquorice Nutrition 0.000 claims abstract description 17
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 16
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 16
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 16
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 16
- 240000007594 Oryza sativa Species 0.000 claims abstract description 16
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 16
- 235000009566 rice Nutrition 0.000 claims abstract description 16
- 241000935235 Fritillaria meleagris Species 0.000 claims abstract description 15
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 15
- 241000951473 Schizonepeta Species 0.000 claims abstract description 15
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 13
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 13
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 13
- 241000270666 Testudines Species 0.000 claims abstract description 13
- 241000131329 Carabidae Species 0.000 claims abstract description 11
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 10
- 244000170916 Paeonia officinalis Species 0.000 claims abstract description 10
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract 5
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 20
- 239000006187 pill Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 238000000227 grinding Methods 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 238000002791 soaking Methods 0.000 claims description 11
- 238000011049 filling Methods 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000008176 lyophilized powder Substances 0.000 claims description 8
- 239000002398 materia medica Substances 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 5
- 210000002421 cell wall Anatomy 0.000 claims description 5
- 238000001125 extrusion Methods 0.000 claims description 5
- 238000000643 oven drying Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- 241000180649 Panax notoginseng Species 0.000 claims description 4
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 4
- 210000000582 semen Anatomy 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 241001489978 Eupolyphaga Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 38
- 231100000331 toxic Toxicity 0.000 abstract description 9
- 230000002588 toxic effect Effects 0.000 abstract description 8
- 239000000654 additive Substances 0.000 abstract description 4
- 230000000996 additive effect Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 description 73
- 239000008280 blood Substances 0.000 description 73
- 241000699670 Mus sp. Species 0.000 description 35
- 239000000463 material Substances 0.000 description 28
- 206010062717 Increased upper airway secretion Diseases 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 21
- 208000026435 phlegm Diseases 0.000 description 21
- 230000001737 promoting effect Effects 0.000 description 19
- 208000002193 Pain Diseases 0.000 description 18
- 230000017531 blood circulation Effects 0.000 description 18
- 230000036407 pain Effects 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 15
- 239000000243 solution Substances 0.000 description 14
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 12
- 108010082126 Alanine transaminase Proteins 0.000 description 12
- 241001570521 Lonicera periclymenum Species 0.000 description 12
- 206010007247 Carbuncle Diseases 0.000 description 11
- 230000009471 action Effects 0.000 description 11
- 238000007710 freezing Methods 0.000 description 11
- 230000008014 freezing Effects 0.000 description 11
- 244000132619 red sage Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 235000008216 herbs Nutrition 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 8
- 208000019425 cirrhosis of liver Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- 241000736919 Pelodiscus sinensis Species 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 108010019077 beta-Amylase Proteins 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 208000014674 injury Diseases 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 240000005979 Hordeum vulgare Species 0.000 description 4
- 235000007340 Hordeum vulgare Nutrition 0.000 description 4
- 206010000269 abscess Diseases 0.000 description 4
- 108090000637 alpha-Amylases Proteins 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000017423 tissue regeneration Effects 0.000 description 4
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 3
- HNOSJVWYGXOFRP-UNPOXIGHSA-N (5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-17-[(2r,4s,5r)-4,5,6-trihydroxy-6-methylheptan-2-yl]-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1CC[C@@]1(C)[C@H]2[C@@H](O)CC2=C([C@@H](C[C@H](O)[C@@H](O)C(C)(C)O)C)CC[C@@]21C HNOSJVWYGXOFRP-UNPOXIGHSA-N 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 3
- HNOSJVWYGXOFRP-UHFFFAOYSA-N Alisol A Natural products CC12CCC(=O)C(C)(C)C1CCC1(C)C2C(O)CC2=C(C(CC(O)C(O)C(C)(C)O)C)CCC21C HNOSJVWYGXOFRP-UHFFFAOYSA-N 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 241000254173 Coleoptera Species 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 241000207923 Lamiaceae Species 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 241001427555 Polyphaga <Blattaria> Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010040925 Skin striae Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 230000003187 abdominal effect Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000010926 purge Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000004243 sweat Anatomy 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 2
- GBJKHDVRXAVITG-UNPOXIGHSA-N Alisol B Chemical compound O([C@@H]1[C@@H](O)C[C@@H](C)C=2CC[C@]3(C)[C@@]4(C)CC[C@H]5C(C)(C)C(=O)CC[C@]5(C)[C@@H]4[C@@H](O)CC3=2)C1(C)C GBJKHDVRXAVITG-UNPOXIGHSA-N 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000018262 Arachis monticola Nutrition 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 240000003421 Dianthus chinensis Species 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 2
- 240000006023 Trichosanthes kirilowii Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QMCLOHXDDPMAMI-UHFFFAOYSA-N alisol B Natural products CC(C)C(=O)C(O)CC(C)C1=C2CC(O)C3C4(C)CCC(=O)C(C)(C)C4CCC3(C)C2(C)CC1 QMCLOHXDDPMAMI-UHFFFAOYSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 235000020232 peanut Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 241000748223 Alisma Species 0.000 description 1
- 235000013291 Alisma plantago aquatica Nutrition 0.000 description 1
- 240000004615 Alisma plantago-aquatica Species 0.000 description 1
- WXHUQVMHWUQNTG-UHFFFAOYSA-N Alisol E 24-acetate Natural products CC12CCC(=O)C(C)(C)C1CCC1(C)C2C(O)CC2=C(C(CC(O)C(OC(C)=O)C(C)(C)O)C)CCC21C WXHUQVMHWUQNTG-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 235000011446 Amygdalus persica Nutrition 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000233788 Arecaceae Species 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 241000963390 Curcuma wenyujin Species 0.000 description 1
- 235000003394 Curcuma wenyujin Nutrition 0.000 description 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 description 1
- 240000009138 Curcuma zedoaria Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241001478385 Eupatorium japonicum Species 0.000 description 1
- 241001489980 Eupolyphaga sinensis Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 241000605372 Fritillaria Species 0.000 description 1
- 241001547125 Fritillaria thunbergii Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000825107 Hierochloe Species 0.000 description 1
- 235000015466 Hierochloe odorata Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 244000236458 Panicum colonum Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000015533 Prunus davidiana Nutrition 0.000 description 1
- 240000002381 Prunus davidiana Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000219100 Rhamnaceae Species 0.000 description 1
- 235000008090 Rheum palmatum Nutrition 0.000 description 1
- 240000001745 Rheum palmatum Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241001072909 Salvia Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 235000010426 Sambucus chinensis Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000951376 Schizonepeta tenuifolia Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000736917 Trionyx Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- WXHUQVMHWUQNTG-JSWHPQHOSA-N [(3r,4s,6r)-2,4-dihydroxy-6-[(5r,8s,9s,10s,11s,14r)-11-hydroxy-4,4,8,10,14-pentamethyl-3-oxo-1,2,5,6,7,9,11,12,15,16-decahydrocyclopenta[a]phenanthren-17-yl]-2-methylheptan-3-yl] acetate Chemical compound C([C@@]12C)CC(=O)C(C)(C)[C@@H]1CC[C@@]1(C)[C@H]2[C@@H](O)CC2=C([C@@H](C[C@H](O)[C@@H](OC(C)=O)C(C)(C)O)C)CC[C@@]21C WXHUQVMHWUQNTG-JSWHPQHOSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000003814 hair luster Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000012674 herbal formulation Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 208000037805 labour Diseases 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- -1 low dose (50mg/kg) Substances 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 235000021227 peanut soup Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000036632 reaction speed Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000018655 severe necrosis Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000036228 toxication Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/586—Turtles; Tortoises, e.g. terrapins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8966—Fritillaria, e.g. checker lily or mission bells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Insects & Arthropods (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal preparation for treating hepatic fibrosis and a preparation method thereof, wherein the Chinese medicinal preparation is prepared from the following raw material medicaments in part by weight: 10-100 parts of rhizoma alismatis, 5-30 parts of thunberg fritillary bulb, 10-100 parts of turtle shell, 5-20 parts of fructus aurantii, 1-10 parts of liquorice, 5-30 parts of herba lycopi, 1-15 parts of ligusticum wallichii, 1-20 parts of honeysuckle, 1-10 parts of rheum officinale, 5-50 parts of pseudo-ginseng, 1-20 parts of cassia bark, 10-30 parts of schizonepeta spike, 5-15 parts of ground beetle, 10-30 parts of fringed pink, 5-30 parts of peach kernel, 5-20 parts of salvia miltiorrhiza, 5-30 parts of red paeony root, 5-30 parts of radix curcumae, 10-40 parts of fried rice sprout, 10-40 parts of fried malt and 5-30 parts of Chinese date. The invention has obvious curative effect of treating hepatic fibrosis; meanwhile, the formula of the invention does not contain any chemical additive, and the invention has safe and reliable taking and no toxic or side effect.
Description
Technical Field
The invention relates to a Chinese medicinal preparation for treating hepatic fibrosis and a preparation method thereof, belonging to the technical field of pharmacy.
Background
Hepatic fibrosis is a pathophysiological process, which refers to abnormal proliferation of connective tissue in the liver caused by various pathogenic factors. Any liver injury has liver fibrosis in the process of liver repair and healing, and if the injury factor cannot be removed for a long time, the fibrosis process can be continuously developed into liver cirrhosis for a long time.
There are many causes of hepatic fibrosis, and viral hepatitis, alcoholic liver, fatty liver, autoimmune diseases, etc. are common in clinic. Anti-hepatic fibrosis treatment mainly comprises: removing pathogenic factors aiming at the primary disease, such as anti-hepatitis B and hepatitis C virus therapy, anti-schistosomiasis therapy, alcohol withdrawal and the like. The treatment aiming at the hepatic fibrosis is carried out, for example, by inhibiting inflammation or lipid peroxidation, or inhibiting the proliferation and activation of hepatic stellate cells, promoting the degradation of collagen and the like.
At present, most of anti-hepatic fibrosis treatments on the market are targeted means formed by aiming at specific causes, hepatic fibrosis has no particularly obvious clinical symptoms strictly speaking, and mainly has clinical symptoms of hepatitis caused by damage of the liver by various factors or further aggravation of liver cirrhosis, so that the existing technologies or medicines are difficult to treat or prevent hepatic fibrosis, and therefore, the search of safe and effective medicines for treating hepatic fibrosis in traditional Chinese medicines is urgently needed.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine preparation for treating hepatic fibrosis and a preparation method thereof. The invention has obvious curative effect of treating hepatic fibrosis; meanwhile, the formula of the invention does not contain any chemical additive, and the invention has safe and reliable taking and no toxic or side effect.
In order to solve the technical problems, the technical scheme provided by the invention is as follows: a traditional Chinese medicine preparation for treating hepatic fibrosis is prepared from the following raw material medicines in parts by weight: 10-100 parts of rhizoma alismatis, 5-30 parts of thunberg fritillary bulb, 10-100 parts of turtle shell, 5-20 parts of fructus aurantii, 1-10 parts of liquorice, 5-30 parts of herba lycopi, 1-15 parts of ligusticum wallichii, 1-20 parts of honeysuckle, 1-10 parts of rheum officinale, 5-50 parts of pseudo-ginseng, 1-20 parts of cassia bark, 10-30 parts of schizonepeta spike, 5-15 parts of ground beetle, 10-30 parts of fringed pink, 5-30 parts of peach kernel, 5-20 parts of salvia miltiorrhiza, 5-30 parts of red paeony root, 5-30 parts of radix curcumae, 10-40 parts of fried rice sprout, 10-40 parts of fried malt and 5-30 parts of Chinese date.
The traditional Chinese medicine preparation for treating hepatic fibrosis is prepared from the following raw material medicines in parts by weight: 10-50 parts of rhizoma alismatis, 5-20 parts of thunberg fritillary bulb, 10-50 parts of turtle shell, 5-15 parts of fructus aurantii, 1-8 parts of liquorice, 10-20 parts of herba lycopi, 1-10 parts of ligusticum wallichii, 5-15 parts of honeysuckle, 2-8 parts of rheum officinale, 10-30 parts of pseudo-ginseng, 5-15 parts of cassia bark, 15-25 parts of schizonepeta spike, 8-13 parts of ground beetle, 15-25 parts of fringed pink, 10-20 parts of peach kernel, 10-18 parts of salvia miltiorrhiza, 10-20 parts of red paeony root, 10-20 parts of radix curcumae, 15-30 parts of fried rice sprout, 15-30 parts of fried malt and 10-20 parts of Chinese date.
The traditional Chinese medicine preparation for treating hepatic fibrosis is prepared from the following raw material medicines in parts by weight: 30 parts of rhizoma alismatis, 15 parts of thunberg fritillary bulb, 30 parts of turtle shell, 10 parts of fructus aurantii, 5 parts of liquorice, 10 parts of herba lycopi, 8 parts of ligusticum wallichii, 8 parts of honeysuckle, 5 parts of rheum officinale, 12 parts of pseudo-ginseng, 10 parts of cassia bark, 20 parts of schizonepeta spike, 10 parts of ground beetle, 20 parts of fringed pink, 10 parts of peach kernel, 10 parts of salvia miltiorrhiza, 10 parts of red paeony root, 10 parts of radix curcumae, 15 parts of fried rice sprout, 15 parts of fried malt and 15 parts of Chinese date.
The traditional Chinese medicine preparation for treating hepatic fibrosis is decoction, powder, tablets, capsules or pills.
The traditional Chinese medicine preparation for treating hepatic fibrosis is a pill.
The preparation method of the traditional Chinese medicine preparation for treating hepatic fibrosis comprises the following steps:
(1) ultrafine grinding Alismatis rhizoma, Bulbus Fritillariae Thunbergii, carapax Trionycis, fructus Aurantii, Notoginseng radix, Eupolyphaga Seu Steleophaga, semen Persicae, Saviae Miltiorrhizae radix, and radix Paeoniae Rubra to obtain ultrafine powder;
(2) adding 5-10 times of water into liquorice, herba lycopi, ligusticum wallichii, honeysuckle, rheum officinale, cassia bark core, schizonepeta spike, dianthus superbus, radix curcumae, fried rice sprout, fried malt and Chinese date, soaking for 30-60 minutes, decocting for 1-3 hours, and filtering to obtain filtrate and dregs;
(3) adding 2-4 times of water into the medicine residues, decocting for 1-2 hours, and filtering to obtain a secondary decoction filtrate; mixing the two filtrates, concentrating to obtain concentrated solution with relative density of 1.4-1.6, and vacuum freeze drying to obtain extract lyophilized powder;
(4) mixing the extract lyophilized powder with the superfine powder, adding medicinal adjuvants and medicinal binder to obtain intermediate soft material, sieving with medicinal sieve of 10-20 mesh, granulating by extrusion to obtain wet granule, and oven drying in hot air drier to obtain pill.
The preparation method of the traditional Chinese medicine preparation for treating hepatic fibrosis comprises the specific steps of placing the raw materials in the step (1) in a freeze dryer, freezing for 4 hours at-55 ℃, taking out and naturally melting for 50min, placing in the freeze dryer again, freezing for 4 hours at-55 ℃, taking out and naturally melting for breaking the cell walls of the raw materials, placing in a planetary ball mill, grinding for 50-55min at 240r/min, wherein the medium filling rate of the planetary ball mill is 27%, and the filling rate of the crushed raw materials is 19%.
In the step (2), the Chinese medicinal preparation is soaked in water at 50-60 ℃, 3 parts of 65% ethanol solution is added in the soaking process, and then the microwave is performed under the microwave power of 180 w.
The invention starts from the perspective of 'phlegm', selects the components of rhizoma alismatis, thunberg fritillary bulb and the like with the functions of reducing phlegm and resolving masses for research, researches the treatment effect of the traditional Chinese medicine composition on hepatic fibrosis mice and analyzes and discusses the action mechanism of the traditional Chinese medicine composition. Zhe Bei mu can resolve phlegm and relieve depression, and Lu Dong can remove abscess and dredge collaterals, the two herbs are combined for resolving phlegm, removing abscess and dredging collaterals. The pathological changes such as the accumulation of body fluid as phlegm, the stagnation of blood as stasis, the hematoma and hyperplasia during the tissue inflammation are probably the material basis for the formation of the phlegm and the stasis, so the control of the inflammation can reduce the generation of the phlegm and the stasis, and the liver protection and anti-inflammatory actions in the related pharmacological research are consistent, so the test shows that the hepatic fibrosis action of the medicine is probably related to the relieving of the hepatic inflammation, and the aim of treating the hepatic fibrosis is achieved by reducing phlegm and removing stasis.
The pharmacological actions of the raw material medicines are as follows:
alisma orientale, school name: alisma plantago-aquatica Linn, perennial aquatic or marsh grass. Can be used for treating nephritis, edema, pyelonephritis, enteritis, diarrhea, dysuresia, etc. In the book of materia medica Zhengyi, ze Xie is best in draining water passage and specially for passing urine, and can promote phlegm and fluid retention, for instance, in the book of materia Medica, it is said that it can promote phlegm and resolve phlegm and fluid retention, but phlegm and fluid retention also accumulates water and stops dampness, so it can only smooth and remove phlegm. Modern researches show that rhizoma alismatis has a protective effect on liver, lipid-soluble part of rhizoma alismatis has an obvious cholesterol-lowering effect and an anti-atherosclerosis effect on experimental hypercholesteremia rabbits, and the separated acetate of the alisol A, B and the alisol A, B, C have the obvious cholesterol-lowering effect except for the alisol B. When added into the feed of experimental hyperlipoidemia mice in an amount of 0.1%, the feed can reduce blood cholesterol by more than 50%, wherein alisol A-24-acetate has the strongest effect. The ethanol extract of the alisma orientale, the ethyl acetate extract of the ethanol extract and the like have the effect of reducing blood fat for experimental hypercholesteremia rabbits and mice. The ethyl acetate extract and its residual insoluble in acetic acid-water are most effective. The ethyl acetate extract is orally taken at a dose of 1g/kg per day, and has obvious cholesterol lowering effect on normal mice fed with common feed. The orthotopic marking method proves that alisol A has the capacity of inhibiting the esterification of cholesterol in small intestines of mice, and can reduce the absorption rate of cholesterol in the small intestines of the mice by 34 percent without influencing the absorption of linoleic acid. Reducing cholesterol can reduce liver burden, and prevent hepatic fibrosis and liver cirrhosis.
The Bulbus Fritillariae Thunbergii is dried bulb of Fritillaria thunbergii Miq. Zhejiang fritillaria is bitter and cold in property, can clear heat and resolve phlegm, especially has remarkable effects of relieving depression and dissipating stagnation, is a common medicine for treating scrofula, sore and carbuncle swelling toxin, and has the effects of clearing heat, resolving phlegm, relieving cough, detoxifying, resolving masses and resolving carbuncle. The combination of alisma rhizome and thunberg fritillary bulb can dispel phlegm-damp and disperse phlegm stagnation.
Carapax Trionycis is, a dorsal beetle of Trionychidae Trionyx sinensis Weigemann of Trionychidae Trionyx sinensis Wigemann, has effects of dorsal beetle of Trionyx sinensis Weigemann of Trionyx sinensis Wigemann, and has effects of dorsal beetle of Trionyx sinensnariae Trionyx sinensis Weigemann of Trionyx sinensis Wigemann.
Fructus Aurantii, Citrus aurantium L. of Rutaceae is close to mature fruit, has effects of regulating qi-flowing, relieving epigastric distention, activating stagnancy and relieving flatulence, and pharmacological research shows that it has effects of increasing blood pressure; inhibiting urine; (ii) anti-shock; inhibiting gastrointestinal motility; has dual effects of excitation or inhibition on uterus.
Licorice, another name: the traditional Chinese medicine comprises the components of Chinese elder, sweet grass, Ural liquorice and radix glycyrrhizae, belongs to perennial herbs in leguminosae and liquorice, and the medicinal parts are roots and rhizomes, and are mainly used for regulating the middle warmer and relieving urgency, moistening lung, detoxifying and harmonizing the drugs. It is stir-baked to treat weakness of spleen and stomach, poor appetite, abdominal pain, loose stool, fatigue, fever, consumptive lung disease, cough, palpitation, fright epilepsy; unprocessed, for swollen and sore throat, peptic ulcer, abscess, deep-rooted carbuncle, sores and ulcers, relieving toxicity of herbs and food poisoning, Rihuazi Ben Cao: "Ansouding" soul. Tonify five kinds of overstrain and seven kinds of injuries, all of which are deficiency, palpitation, vexation and amnesia. Unblocking nine orifices, benefiting all vessels, replenishing vital essence and nourishing qi, strengthening bones and muscles, and relieving cold and heat.
Herba Lycopi is the dried aerial part of Polyopus lucidus Turcz.vat. hirtus Regel of Labiatae, and has effects of promoting blood circulation, regulating menstruation, removing blood stasis, resolving carbuncle, inducing diuresis and relieving swelling. Can be used for treating menoxenia, amenorrhea, dysmenorrhea, puerperal blood stasis and abdominal pain, skin ulcer, carbuncle, toxic swelling, edema, and ascites.
Chuanxiong rhizome, the name: ligusticum chuanxiong Hort, a cultivated plant, is commonly used for promoting blood circulation and promoting qi circulation, dispelling wind and relieving pain, and Ligusticum wallichii is pungent, warm, fragrant and dry, and can disperse and ascend to the vertex; it enters the blood system and goes down to reach the blood sea. Promoting blood circulation and removing blood stasis, and is suitable for various diseases caused by blood stasis; it has good effect in dispelling pathogenic wind and relieving pain, and can be used for treating headache, rheumatalgia, etc. Xiren is that Chuan Xiong is a qi-flowing medicine in blood, but it has the functions of dispersing acrid, relieving depression, dredging and relieving pain.
Honeysuckle, known as Lonicera japonica Thunb, has the effects of clearing away heat and toxic materials. It can be used for treating fever due to affection of exogenous wind-heat or epidemic febrile disease, heatstroke, toxic heat, dysentery, carbuncle, furuncle, pharyngitis, and various infectious diseases. Pharmacological research shows that the traditional Chinese medicine composition has the effects of resisting pathogenic microorganisms, resisting virus and inflammation, promoting phagocytic function of inflammatory cells, reducing blood fat, exciting central nerves, exciting the central nerves and having obvious cytotoxic effect on sarcoma S180 and Ehrlich ascites carcinoma; record of materia medica asking for truth: honeysuckle flower, flos Lonicerae, all written in all books, is indicated as tonifying deficiency and nourishing blood, and also indicated as entering lung to dispel heat, and can be used for treating malignant boil, intestine , carbuncle, abscess and hemorrhoids and fistula, and is the major therapeutic agent for surgical poison treatment. Thus, the two branches are similar. People who are not familiar with the book to tonify deficiency, because they are sweet in fragrance and flavor, even though they are going into the interior to dispel heat, they are not able to damage them quickly; in the word, blood-nourishing herbs are also called Duke's blood nourishing because they are toxic and blood-coagulation-inducing herbs and take the actions of Du Qi to relieve toxicity. The ear belonging to the category of heat-clearing and toxicity-removing herbs is a good choice for treating all diseases such as superficial infection without any reason, so it is good at clearing heat and relieving heat with its qi cold. If the person takes the pillow for a long time, the person can lose weight and prolong the life, but the person can not carry the pillow. The ancient people who have the same type of herbs and the herbs with the same type of herbs are not the best to be considered as the therapeutic effect of herbs. "
The radix et rhizoma Rhei is rhizome of Rheum palmatum L, Rheum tanguticum Maxim or Rheum officinale Baill of Polygonaceae, and has effects of clearing away heat and toxic materials, removing food stagnation, and removing blood stasis. Treating excessive heat constipation, delirium, fever, food stagnation, abdominal fullness, dysentery, tenesmus, stasis, amenorrhea, abdominal mass, epidemic heat, acute conjunctivitis, hematemesis, epistaxis, yang jaundice, edema, stranguria with turbid urine, carbuncle, sore, and injury due to fire and dampness. Purging heat, promoting bowel movement, cooling blood, removing toxic substances, removing blood stasis, and dredging channels. Can be used for treating constipation due to excessive heat, abdominal pain due to stagnation, dysentery, and jaundice due to damp-heat.
Notoginseng radix is dried root of Panax notoginseng (Burk.) F.H.Chen of Araliaceae. Has effects of removing blood stasis, stopping bleeding, promoting blood circulation, and relieving pain. It can be used for treating hemorrhage, traumatic injury, and swelling and pain due to blood stasis.
The cassia bark core has the effects of bitter entering the heart, pungent movement and blood circulation elimination, blood induction, sweat elimination and suppuration, internal support, carbuncle, cellulitis and acne, essence benefiting, eyesight improvement, stasis elimination and tissue regeneration promotion, labor injury compensation, waist and knee warming and muscle and bone reunion; the compendium records: rou Gui goes downward to nourish fire, so it is called kidney bitter and dry, urgent to eat pungent and moisten, to open striae and striae, to cause body fluid and to ventilate its qi. In the section of Shenghui Fang, Gui Xin enters heart to induce blood, sweat and suppuration. The heat in the palms, shaoyin, monarch fire and jueyin, which are also in harmony with the vital gate.
Herba Schizonepetae is dry flower spike of Schizonepeta tenuifolia Briq. of Labiatae, and has effects of relieving exterior syndrome, dispelling pathogenic wind, promoting eruption, and eliminating sore.
The ground beetle is a female dried body of Eupolyphaga sinensis or stereophaga plancyi (Boleny) of the cockroach, and has the following functions and main indications: to break blood stasis and continue the muscles and bones. Can be used for treating fracture of tendons and bones, amenorrhea due to blood stasis, and abdominal mass.
Dianthus superbus L is dry aerial part of Dianthus superbus L. or Dianthus chinensis L. of Dianthus superbus of Dianthus family. Has the effects of inducing diuresis for treating stranguria, promoting blood circulation and stimulating the menstrual flow, and is recorded in the golden Kui Fang: dysuria with water vapor, the trichosanthes kirilowii and pink herb pill is mainly characterized by: two and half dianthus superbus, two and two trichosanthes kirilowii roots, one giant aconite, three and two poria cocos and sweet potato which are respectively in the form of powder, honey and pills which are large in size. Three pills for one time and three pills for the other time. Unknown, it is as good as seven and eight pills. It is also known as small and convenient, and moderate abdominal temperature. 0
Peach kernel is dry mature seed of Prunus persica (L.) Batsch or Prunus davidiana (Carr.) Franch of Rosaceae, and has effects of promoting blood circulation, removing blood stasis, resolving carbuncle, expelling pus, loosening bowel, and relieving constipation. It enters heart and liver blood system well, and can activate blood and unblock meridians, dispel stasis and alleviate pain, so it is indicated for obstruction of blood stasis and mass accumulation due to unsmooth blood flow. The "pharmacy records" are: peach kernel, semen Persicae, bitter in flavor, can purge blood heat, moisten body and nourish intestinal dryness. If the Lian Pi is smashed for multiple purposes, it can break and store blood, dispel water, induce pain, numbness of limbs, hemiplegia and pain of feet, so it can promote blood circulation, remove blood stasis and promote tissue regeneration. Getting up without oneself: liver is the source of blood, blood accumulation causes dryness of liver qi, bitter and urgent liver, and urgent and sweet food is treated by slow action. Tao ren is sweet in flavor and acts as a liver-soothing and blood-dissipating herb. The book of thought differentiation of materia Medica: tao ren is a liver herb for dispelling blood stasis and also has the action of dispersing skin and striae.
The Saviae Miltiorrhizae radix is dried root and rhizome of Salvia milithiorrhiza bge of Labiatae, and has bitter taste, slightly cold property, and heart and liver meridian entered. Has the effects of promoting blood circulation, removing blood stasis, stimulating the menstrual flow, relieving pain, clearing away the heart-fire, relieving restlessness, cooling blood, eliminating carbuncle, promoting blood circulation, treating dysmenorrhea, removing blood stasis and relieving pain. The record in Shen nong Ben Cao Jing: "bitter in taste and slightly cold in nature" is mainly indicated for … … accumulation, mass breaking and mass removing. The "materia medica justice" also states: dan Shen is specialized in blood system and has the actions of activating blood and promoting blood circulation, and resolving stasis and stagnation by reaching viscera. The "materia medica summary" records: dan Shen is also indicated for blood system, removing stagnation and promoting tissue regeneration, regulating menstruation and regulating pulse.
Radix Paeoniae Rubra is dry root of Ranunculaceae plant radix Paeoniae Rubra or radix Paeoniae Rubra, is bitter and slightly cold, and has effects of clearing heat and cooling blood, promoting blood circulation and removing blood stasis; for example, it is recorded in Ben Cao Jing Shu (herbal Jing Shu): the red-colored and broken-powder of mu Shao is mainly used for relieving pain and is specialized in blood system of liver and home, so it is mainly used for abdominal pain due to pathogenic qi. It is mainly used for removing blood impediment and dissipating hard mass, blood stasis causes cold and heat, blood circulation causes cold and heat self-stopping, blood impediment and hernia are all formed by blood coagulation stagnation, and blood stagnation of limbs causes impediment and hernia self-elimination. Cool the liver to dredge the blood vessels, the liver governs blood and enters the liver to promote blood circulation, so disperse blood stasis and expel blood stasis.
The radix Curcumae is dried root tuber of Curcuma wenyujin Y, H.Chenet C.Ling, Curcuma longa LongaL, Curcuma kwangtungakwangsiensis S.G.Lee et C.F.Liang or Curcuma zedoaria phareocauli Val; yu jin is the qi-flowing herb in blood, not only activating blood and alleviating pain, but also moving qi, and also has the actions of promoting bile flow and removing jaundice, cooling blood and stopping bleeding. Its pungent flavor can disperse energy and move, and can activate blood circulation to dissipate blood stasis, and move qi and relieve depression to alleviate pain, as recorded in the book Ben Cao Hui Yan: yu jin is also indicated for clearing qi and resolving phlegm, and dissipating blood stasis. It is mild in nature, can dispel stasis, direct adverse qi, ascends to the vertex, and is good at moving the lower energizer, and is the most suitable for patients with stagnation of qi, blood, and phlegm in the heart, lung, liver, stomach, and stomach, so it is indicated for chest and stomach pain, distending fullness in the hypochondrium, pain attacking the abdomen, and poor appetite. The book Ben Cao Jing Yi: yu jin, bitter and cold in flavor, means that qi is cold and descending well, and bitter and purging well. For those with blood stasis, the main reason is that the pathogen is blood accumulation, especially has the effect of breaking the malignant blood, because the pathogen is blood accumulation, the blood is accumulated, the blood is malignant blood, the blood flows upwards reversely, and comes out from mouth and nose, the blood is epistaxis and hematemesis, the blood flows downwards, and comes out from urinating and defecating, the pain is stranguria with blood, and the pain is hematuria, i.e. the blood stasis of incised wound is not removed, the blood is not broken, and the tissue regeneration cannot be promoted.
The parched rice sprout is mature fruit of millet of Gramineae, processed to sprout, and parched; has the effects of treating indigestion, fullness, diarrhea and anorexia.
The roasted malt is also called barley malt, barley \31989, barley \31989and barley wool, and is mainly used for treating indigestion, abdominal distending pain, spleen deficiency and poor appetite, milk sweat and stasis, breast distending pain and breast weaning of women; modern research shows that roasted malt contains alpha and beta amylase; starch is a mixture of sugar starch and gum starch, the glucose molecules that make up the sugar starch are linked by alpha-1, 4 glycosidic linkages and are in a linear arrangement. The glue starch is formed by cross arrangement of a plurality of short straight chain polyglucose. Amylopectin molecules have alpha-1, 6 glucosidic bonds in addition to alpha-1, 4 glucosidic bonds. Alpha and beta amylases can hydrolyze alpha-1, 4 glycosidic bonds and have no effect on alpha-1, 6 glycosidic bonds. Beta-amylase is able to hydrolyze the sugar starch completely to maltose, and alpha-amylase breaks it down to short direct bond polyglucose (i.e., dextrin), which in turn is able to hydrolyze the beta-amylase to maltose. Starch can thus be broken down into maltose and dextrin by the action of alpha and beta amylases. The malt decoction has a slight promoting effect on the secretion of gastric acid and pepsin. The roasted malt also has the function of reducing blood sugar, and the 5 percent injection prepared by the refined product of malt residue water extraction and alcohol precipitation is injected into rabbits for 200mg, so that the blood sugar can be reduced by 40 percent or more, and the recovery is mostly realized after 7 hours.
The Chinese date is a mature fruit of the Rhamnaceae plant Chinese date, and has the following main functions: invigorating spleen and regulating stomach function, benefiting qi and promoting fluid production, regulating yingfen and weifen, and removing drug toxicity. It is indicated for deficiency of stomach and food, spleen weakness, loose stool, qi, blood and body fluids deficiency, disharmony between ying and wei, palpitation. The traditional Chinese medicine composition has the effects of resisting tumor and I-type allergic reaction in pharmacological research and inhibiting central nerves, can reduce the level of serum glutamic-pyruvic transaminase in clinical tests, and is effective for patients with high serum transaminase activity in patients with acute and chronic hepatitis and cirrhosis by taking 1 dose of red date peanut soup (red date, peanut and rock candy respectively 1 two times before sleeping every night, firstly decocting the peanut and then adding the red date rock candy) for 30 days as a treatment course and observing 12 cases.
Compared with the prior art, the traditional Chinese medicine preparation for preventing and treating hepatic fibrosis adopts the pharmacological action of reducing phlegm and removing stasis of traditional Chinese medicines, reduces the inflammation of the liver by using multiple components, and has obvious advantages in preventing and treating hepatic fibrosis; tests show that the Chinese medicinal preparation has remarkable curative effect of treating hepatic fibrosis. Meanwhile, the components in the formula of the invention do not contain any chemical additive, and the invention has safe and reliable taking and no toxic or side effect.
Drawings
FIG. 1 is a pathological observation of HE staining of mouse liver tissue.
Detailed Description
The present invention will be further described with reference to the following examples and drawings, but the present invention is not limited thereto.
Example 1: a traditional Chinese medicine preparation for treating hepatic fibrosis is prepared from the following raw material medicines in parts by weight: 50g of rhizoma alismatis, 20g of thunberg fritillary bulb, 10g of turtle shell, 15g of fructus aurantii, 1g of liquorice, 5g of herba lycopi, 10g of ligusticum wallichii, 8g of honeysuckle, 10g of rheum officinale, 15g of pseudo-ginseng, 10g of cassia bark, 10g of schizonepeta spike, 5g of ground beetle, 25g of fringed pink, 25g of peach kernel, 20g of salvia miltiorrhiza, 15g of red paeony root, 10g of radix curcumae, 30g of fried rice sprout, 10g of fried malt and 20g of Chinese date.
The preparation method of the traditional Chinese medicine preparation comprises the following steps:
(1) ultrafine grinding rhizoma alismatis, thunberg fritillary bulb, turtle shell, fructus aurantii, pseudo-ginseng, Chinese polyphaga, peach kernel, salvia miltiorrhiza and radix paeoniae rubra to obtain ultrafine powder, wherein the ultrafine grinding process comprises the steps of firstly placing the materials in a freeze dryer, freezing the materials at the temperature of minus 55 ℃ for 4 hours, taking the materials out to naturally melt for 50 minutes, placing the materials in the freeze dryer again, freezing the materials at the temperature of minus 55 ℃ for 4 hours, taking the materials out to naturally melt for breaking the cell walls of the raw materials, then placing the materials in a planetary ball mill, grinding the materials at the speed of 240r/min for 50-55 minutes, wherein the medium filling rate of the planetary ball mill is 27%, and the filling rate of the ground raw materials is 19%;
(2) adding 8 times of water into liquorice, herba lycopi, ligusticum wallichii, honeysuckle, rheum officinale, cassia bark core, schizonepeta spike, dianthus superbus, radix curcumae, fried rice sprout, fried malt and Chinese date, soaking for 50 minutes by using water at the temperature of 50-60 ℃, adding 3 parts of 65% ethanol solution in the soaking process, then carrying out microwave treatment under the microwave power of 180w, decocting for 1.5 hours, and filtering to obtain filtrate and dregs;
(3) adding 4 times of water into the dregs of a decoction, decocting for 2 hours, and filtering to obtain a secondary decoction filtrate; mixing the two filtrates, concentrating to obtain a concentrated solution with a relative density of 1.4, and freeze-drying the concentrated solution under vacuum to obtain extract freeze-dried powder;
(4) mixing the extract lyophilized powder with the superfine powder, adding medicinal adjuvants and medicinal binder to obtain intermediate soft material, sieving with medicinal sieve of 10 mesh, granulating by extrusion to obtain wet granule, oven drying the wet granule in hot air drier, adding medicinal adjuvants to obtain pill of 0.75 g/pill;
(3) the eating method and the eating amount of the traditional Chinese medicine preparation are as follows: the composition is administered three times a day, 5-10 granules each time, for 2 months.
Example 2: a traditional Chinese medicine preparation for treating hepatic fibrosis is prepared from the following raw material medicines in parts by weight: 40g of rhizoma alismatis, 30g of thunberg fritillary bulb, 50g of turtle shell, 5g of fructus aurantii, 5g of liquorice, 20g of herba lycopi, 5g of ligusticum wallichii, 15g of honeysuckle, 5g of rheum officinale, 40g of pseudo-ginseng, 5g of cassia bark, 10g of schizonepeta spike, 5g of ground beetle, 10g of fringed pink, 15g of peach kernel, 5g of salvia miltiorrhiza, 25g of red paeony root, 5g of radix curcumae, 15g of fried rice sprout, 20g of fried malt and 10g of Chinese date.
The preparation method of the traditional Chinese medicine preparation comprises the following steps:
(1) ultrafine grinding rhizoma alismatis, thunberg fritillary bulb, turtle shell, fructus aurantii, pseudo-ginseng, Chinese polyphaga, peach kernel, salvia miltiorrhiza and radix paeoniae rubra to obtain ultrafine powder, wherein the ultrafine grinding process comprises the steps of firstly placing the materials in a freeze dryer, freezing the materials at the temperature of minus 55 ℃ for 4 hours, taking the materials out to naturally melt for 50 minutes, placing the materials in the freeze dryer again, freezing the materials at the temperature of minus 55 ℃ for 4 hours, taking the materials out to naturally melt for breaking the cell walls of the raw materials, then placing the materials in a planetary ball mill, grinding the materials at the speed of 240r/min for 50-55 minutes, wherein the medium filling rate of the planetary ball mill is 27%, and the filling rate of the ground raw materials is 19%;
(2) adding 9 times of water into liquorice, herba lycopi, ligusticum wallichii, honeysuckle, rheum officinale, cassia bark core, schizonepeta spike, dianthus superbus, radix curcumae, fried rice sprout, fried malt and Chinese date, soaking for 35 minutes in water at the temperature of 50-60 ℃, adding 3 parts of 65% ethanol solution in the soaking process, then carrying out microwave treatment under the microwave power of 180w, decocting for 2.5 hours, and filtering to obtain filtrate and dregs;
(3) decocting the residue with 2.5 times of water for 1.5 hr, and filtering to obtain secondary decoction filtrate; mixing the two filtrates, concentrating to obtain a concentrated solution with a relative density of 1.6, and freeze-drying the concentrated solution under vacuum to obtain extract freeze-dried powder;
(4) mixing the lyophilized powder with the superfine powder, adding medicinal adjuvants and medicinal binder to obtain intermediate soft material, sieving with 20 mesh sieve, granulating by extrusion to obtain wet granule, oven drying in hot air drier, and adding medicinal adjuvants to obtain pill of 0.75 g/pill.
(3) The eating method and the eating amount of the traditional Chinese medicine preparation are as follows: the composition is administered three times a day, 5-10 granules each time, for 2 months.
Example 3: a traditional Chinese medicine preparation for treating hepatic fibrosis is prepared from the following raw material medicines in parts by weight: 30g of rhizoma alismatis, 15g of thunberg fritillary bulb, 30g of turtle shell, 10g of fructus aurantii, 5g of liquorice, 10g of herba lycopi, 8g of ligusticum wallichii, 8g of honeysuckle, 5g of rheum officinale, 12g of pseudo-ginseng, 10g of cassia bark, 20g of schizonepeta spike, 10g of ground beetle, 20g of fringed pink, 10g of peach kernel, 10g of salvia miltiorrhiza, 10g of red paeony root, 10g of radix curcumae, 15g of fried rice sprout, 15g of fried malt and 15g of Chinese date.
The preparation method of the traditional Chinese medicine preparation comprises the following steps:
(1) ultrafine grinding rhizoma alismatis, thunberg fritillary bulb, turtle shell, fructus aurantii, pseudo-ginseng, Chinese polyphaga, peach kernel, salvia miltiorrhiza and radix paeoniae rubra to obtain ultrafine powder, wherein the ultrafine grinding process comprises the steps of firstly placing the materials in a freeze dryer, freezing the materials at the temperature of minus 55 ℃ for 4 hours, taking the materials out to naturally melt for 50 minutes, placing the materials in the freeze dryer again, freezing the materials at the temperature of minus 55 ℃ for 4 hours, taking the materials out to naturally melt for breaking the cell walls of the raw materials, then placing the materials in a planetary ball mill, grinding the materials at the speed of 240r/min for 50-55 minutes, wherein the medium filling rate of the planetary ball mill is 27%, and the filling rate of the ground raw materials is 19%;
(2) adding 8 times of water into liquorice, eupatorium japonicum, ligusticum wallichii, honeysuckle, rheum officinale, cassia bark core, schizonepeta spike, dianthus superbus, radix curcumae, fried rice sprout, fried malt and Chinese date, soaking for 45 minutes in water at the temperature of 50-60 ℃, adding 3 parts of 65% ethanol solution in the soaking process, then carrying out microwave treatment under the microwave power of 180w, decocting for 2 hours, and filtering to obtain filtrate and dregs;
(3) adding 2 times of water into the dregs of a decoction, decocting for 1.5 hours, and filtering to obtain a secondary decoction filtrate; mixing the two filtrates, concentrating to obtain concentrated solution with relative density of 1.5, and vacuum freeze drying to obtain extract lyophilized powder;
(4) mixing the extract lyophilized powder with the superfine powder, adding medicinal adjuvants and medicinal binder to obtain intermediate soft material, sieving with medicinal sieve of 15 mesh, granulating by extrusion to obtain wet granule, oven drying the wet granule in hot air drier, adding medicinal adjuvants to obtain pill of 0.75 g/pill;
(3) the eating method and the eating amount of the traditional Chinese medicine preparation are as follows: the composition is administered three times a day, 5-10 granules each time, for 2 months.
Example 4: animal experiments:
1. experimental Material
1.1 Chinese medicinal preparation for treating hepatic fibrosis
In this example, the best effective herbal formulation provided in example 3 was selected as the dose group for testing.
Distilled water was selected as a normal control for comparison in this example.
1.2 animals
30 SPF male mice of 8 weeks old are provided by Experimental animals center of Hospital of medical sciences, Zhejiang province, with animal license number SCXK Zhe-20180055.
1.3 drugs and reagents
Carbon tetrachloride (CCL)4180503, olive oil, physiological saline, serum, etc. provided by Nanjing's Biochemical Limited.
2. Experimental methods
2.1 preparation of mouse hepatic fibrosis model
Randomly dividing 30 mice into 2 groups, randomly dividing normal control group mice into 5 mice, breeding 25 mice in a molding group, breeding 5 mice per cage, molding by the molding group, and giving 35% CCL4Olive oil solution 1 ml/kg-1Preparing a hepatic fibrosis model by subcutaneous injection, and performing continuous 6 weeks for 3 times per week; the normal group was given 1 ml/kg of 0.9% physiological saline-1Injecting subcutaneously for 3 times per week for 6 weeks; during the period of standard feed feeding, the weight, diet, spirit and gross bin changes of the mice are closely observed during the modeling experiment period, and the mice in the modeling group in the sixth week can be found to have hepatic fibrosis through pathological observation.
2.2 Experimental groups and administrations
Dividing 5 male normal mice into a normal group a; dividing 25 male mice infected with hepatic fibrosis in the modeling group into four administration groups of ABCD according to 5 mice per group, wherein the four administration groups are a group A with low dosage of traditional Chinese medicine preparation, a group B with medium dosage of traditional Chinese medicine preparation, a group C with high dosage of traditional Chinese medicine preparation, a group D without administration, and the remaining mice with the modeling group without administration are called modeling control groups. All mice are raised in a constant-temperature and constant-humidity environment, water is freely drunk, standard granulated feeds are fed, the feeds are replaced every week, and the feeding cages are cleaned for 1-2 times; diluting mice in group A, B and C with three doses of physiological saline, including low dose (50mg/kg), medium dose (100mg/kg) and high dose (150mg/kg), respectively, and performing intragastric administration with the dosage of 0.5 ml/mouse for 1 time/day; the total treatment period was 8 weeks. After the 14 th week, namely after treatment, all mice adopt an eyeball blood taking mode to reserve 1-2ml of blood specimen, then are killed by adopting a cervical vertebra dislocation method and dissect and separate out livers, reserve soybean liver tissues and put in a fixing solution (4% paraformaldehyde) for fixation, reserve two liver tissues and put in a freezing tube, put the freezing tube in an ice block for quick freezing, and then quickly transfer to a refrigerator at minus 80 ℃ for storage.
2.3 detection of various indexes
2.3.1 serum liver function routine index test (ALT, AST)
2.3.1.1 serum separation: and (3) placing a blood sample left after blood is taken from mouse eyeballs in a 37 ℃ water bath box for incubation for 30min, then centrifuging for 10min (the rotating speed is 4000 rpm), taking upper serum after centrifugation is finished, subpackaging the upper serum in an Enpendoff tube, and storing the separated serum in a refrigerator at the temperature of-80 ℃ for detection.
2.3.1.2 liver function general index ALT, AST detection: measuring alanine Aminotransferase (ALT) and aspartate Aminotransferase (ALT) in the serum of the mouse by using a full-automatic biochemical analyzer Hitachi7170A
2.4 pathological observations of cases
The method comprises the steps of placing a soybean liver tissue specimen in 4% paraformaldehyde fixing solution for fixing for 24 hours, then replacing with new fixing solution, continuing to fix for 1 hour, taking out, trimming the specimen with a slicing knife, then performing conventional dehydration and paraffin embedding, then slicing with a slicing machine to ensure that the layer thickness is about 4 microns, and performing hematoxylin-eosin (HE) staining on the cut glass slides respectively.
2.5 statistical analysis
The experimental data of ALT and AST indexes of liver function serology are expressed in x +/-s, and SPSS22.0 is used for statistical analysis. And analyzing the significance of the difference of each parameter by using variance, wherein P is less than 0.05 to indicate that the difference has statistical significance.
3. Results of the experiment
3.1 mouse status
The normal control group mice had good mental status, normal diet intake, rapid response, good hair luster, white and soft hair color, good mobility, normal weight gain, and flat abdomen. The mice in the model-making control group can feel yellow, greasy, coarse and young skin fur disease, listlessness, slow action, abdominal distension, abdominal ascites visible in dissection and little water intake from the tenth model-making week. The mental states of ABC three groups of mice in the administration group are obviously improved compared with those in the D group, and the reaction speed, the diet water intake and the hair color are better than those in the control D group.
3.2 serological index results of liver function
Liver function serological index results are shown in table 1, and the dose group ABC of the administered group had a good therapeutic effect on liver function of hepatic fibrosis in mice (P <0.05) compared with the control group D.
TABLE 1 influence of the Chinese medicinal preparation on the mouse liver fibrosis serum index (
n＝20)
1. P <0.05 compared to normal group; 2. p <0.05 compared to group D;
as can be seen from Table 1, the serum ALT and AST of the mice in the control group D are obviously increased compared with the mice in the normal group, and the difference has significant meaning (P is less than 0.05); compared with the control group D, the low-dose group (group A), the medium-dose group (group B) and the high-dose group (group C) of the traditional Chinese medicine preparation have the advantages that ALT and AST in the serum of the mice are reduced, and the difference has statistical significance (P is less than 0.05); compared with the serum ALT and AST of three groups of mice, namely a low dose group (group A), a medium dose group (group B) and a high dose group (group C), the difference has statistical significance (P is less than 0.05), wherein the serum ALT and AST of the mice in the group C are most obviously reduced, and the serum ALT and AST of the mice in the group B are second.
3.3 pathological Observation of HE staining of mouse liver tissue
As shown in the light microscope observation of figure 1, a, b and c in figure 1 are progressive disease graphs of mouse liver fibrosis, and the graphs show that the inflammation of liver cells is obvious, and hyperplasia of degenerated and necrotic liver cells and fibro-desmosis connective tissue is abnormal, which indicates that a liver fibrosis model of a 6-week mouse is successfully established. In fig. 1, D is a diagram of liver cells of normal mice, wherein the diagram shows that the liver cells are normal, the ABCD in fig. 1 respectively corresponds to the liver cell diagram of the ABCD mice in the administration group after 8 weeks of treatment, and it can be seen from the diagram that the liver cells and the position limiting connective tissue of the mice in the dosage group of ABC three groups in the administration group are obviously improved under the treatment of the traditional Chinese medicine preparation of the invention, the proliferation of fibers in a liver tissue junction area and granuloma is rare, the inflammatory response of the junction area is light, no inflammation or a small amount of punctate necrosis is seen in the lobule, and the stem cells of the mice in the group D have severe necrosis.
In conclusion, the invention adopts the multiple components of the traditional Chinese medicine, has the pharmacological effects of reducing phlegm and removing blood stasis, relieves the inflammation of the liver and has obvious advantages in preventing and treating hepatic fibrosis; tests show that the Chinese medicinal preparation has remarkable curative effect of treating hepatic fibrosis. Meanwhile, the components in the formula of the invention do not contain any chemical additive, and the invention has safe and reliable taking and no toxic or side effect.
Claims (7)
1. A traditional Chinese medicine preparation for treating hepatic fibrosis is characterized in that: the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-100 parts of rhizoma alismatis, 5-30 parts of thunberg fritillary bulb, 10-100 parts of turtle shell, 5-20 parts of fructus aurantii, 1-10 parts of liquorice, 5-30 parts of herba lycopi, 1-15 parts of ligusticum wallichii, 1-20 parts of honeysuckle, 1-10 parts of rheum officinale, 5-50 parts of pseudo-ginseng, 1-20 parts of cassia bark, 10-30 parts of schizonepeta spike, 5-15 parts of ground beetle, 10-30 parts of fringed pink, 5-30 parts of peach kernel, 5-20 parts of salvia miltiorrhiza, 5-30 parts of red paeony root, 5-30 parts of radix curcumae, 10-40 parts of fried rice sprout, 10-40 parts of fried malt and 5-30 parts of Chinese date.
2. The Chinese materia medica preparation for treating hepatic fibrosis according to claim 1, wherein: the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-50 parts of rhizoma alismatis, 5-20 parts of thunberg fritillary bulb, 10-50 parts of turtle shell, 5-15 parts of fructus aurantii, 1-8 parts of liquorice, 10-20 parts of herba lycopi, 1-10 parts of ligusticum wallichii, 5-15 parts of honeysuckle, 2-8 parts of rheum officinale, 10-30 parts of pseudo-ginseng, 5-15 parts of cassia bark, 15-25 parts of schizonepeta spike, 8-13 parts of ground beetle, 15-25 parts of fringed pink, 10-20 parts of peach kernel, 10-18 parts of salvia miltiorrhiza, 10-20 parts of red paeony root, 10-20 parts of radix curcumae, 15-30 parts of fried rice sprout, 15-30 parts of fried malt and 10-20 parts of Chinese date.
3. The Chinese materia medica preparation for treating hepatic fibrosis according to claim 2, wherein: the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 30 parts of rhizoma alismatis, 15 parts of thunberg fritillary bulb, 30 parts of turtle shell, 10 parts of fructus aurantii, 5 parts of liquorice, 10 parts of herba lycopi, 8 parts of ligusticum wallichii, 8 parts of honeysuckle, 5 parts of rheum officinale, 12 parts of pseudo-ginseng, 10 parts of cassia bark, 20 parts of schizonepeta spike, 10 parts of ground beetle, 20 parts of fringed pink, 10 parts of peach kernel, 10 parts of salvia miltiorrhiza, 10 parts of red paeony root, 10 parts of radix curcumae, 15 parts of fried rice sprout, 15 parts of fried malt and 15 parts of Chinese date.
4. The Chinese medicinal preparation for treating hepatic fibrosis according to any one of claims 1 to 3, wherein: the Chinese medicinal preparation is in the form of decoction, powder, tablet, capsule or pill.
5. The method for preparing a Chinese medicinal preparation for treating hepatic fibrosis according to any one of claims 1 to 4, wherein the preparation comprises the following steps: the method comprises the following steps:
(1) ultrafine grinding Alismatis rhizoma, Bulbus Fritillariae Thunbergii, carapax Trionycis, fructus Aurantii, Notoginseng radix, Eupolyphaga Seu Steleophaga, semen Persicae, Saviae Miltiorrhizae radix, and radix Paeoniae Rubra to obtain ultrafine powder;
(2) adding 5-10 times of water into liquorice, herba lycopi, ligusticum wallichii, honeysuckle, rheum officinale, cassia bark core, schizonepeta spike, dianthus superbus, radix curcumae, fried rice sprout, fried malt and Chinese date, soaking for 30-60 minutes, decocting for 1-3 hours, and filtering to obtain filtrate and dregs;
(3) adding 2-4 times of water into the medicine residues, decocting for 1-2 hours, and filtering to obtain a secondary decoction filtrate; mixing the two filtrates, concentrating to obtain concentrated solution with relative density of 1.4-1.6, and vacuum freeze drying to obtain extract lyophilized powder;
(4) mixing the extract lyophilized powder with the superfine powder, adding medicinal adjuvants and medicinal binder to obtain intermediate soft material, sieving with medicinal sieve of 10-20 mesh, granulating by extrusion to obtain wet granule, and oven drying in hot air drier to obtain pill.
6. The method for preparing a Chinese medicinal preparation for treating hepatic fibrosis according to claim 5, wherein the preparation comprises the following steps: the ultrafine grinding is specifically that the raw materials in the step (1) are firstly placed in a freeze dryer and frozen for 4 hours at-55 ℃, then are taken out and naturally melted for 50 minutes, and are then placed in the freeze dryer and frozen for 4 hours at-55 ℃, then are taken out and naturally melted for breaking the cell wall of the raw materials, and then are placed in a planetary ball mill and ground for 50-55 minutes at 240r/min, the medium filling rate of the planetary ball mill is 27%, and the filling rate of the ground raw materials is 19%.
7. The method for preparing a Chinese medicinal preparation for treating hepatic fibrosis according to claim 5, wherein the preparation comprises the following steps: in the step (2), soaking with water at 50-60 ℃, adding 3 parts of 65% ethanol solution in the soaking process, and then carrying out microwave treatment under the microwave power of 180 w.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011142360.7A CN112057590A (en) | 2020-10-23 | 2020-10-23 | Chinese medicinal preparation for treating hepatic fibrosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011142360.7A CN112057590A (en) | 2020-10-23 | 2020-10-23 | Chinese medicinal preparation for treating hepatic fibrosis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112057590A true CN112057590A (en) | 2020-12-11 |
Family
ID=73655392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011142360.7A Pending CN112057590A (en) | 2020-10-23 | 2020-10-23 | Chinese medicinal preparation for treating hepatic fibrosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112057590A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102671078A (en) * | 2012-05-28 | 2012-09-19 | 石家庄平安医院有限公司 | Medicine composition for curing myelofibrosis and hepatofibrosis and preparation method of medicine composition |
-
2020
- 2020-10-23 CN CN202011142360.7A patent/CN112057590A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102671078A (en) * | 2012-05-28 | 2012-09-19 | 石家庄平安医院有限公司 | Medicine composition for curing myelofibrosis and hepatofibrosis and preparation method of medicine composition |
Non-Patent Citations (10)
| Title |
|---|
| 张寿山: "《制药厂生产车间新技术新工艺流程与操作技能应用、质量控制及设备运行维护实用全书》", 31 October 2005, 中国医药科技电子出版社 * |
| 张素杰: "中医药抗肝纤维化的治法研究进展", 《河北中医》 * |
| 朱飞叶 等: "化痰行瘀汤对肝纤维化大鼠肝脏超微结构的影响", 《中华中医药杂志》 * |
| 涂燕云等: "软肝汤联合拉米夫定对慢性乙型肝炎肝纤维化的影响", 《辽宁中医杂志》 * |
| 陈国中 等: "中医化痰行瘀法抗肝纤维化研究进展", 《浙江中西医结合杂志》 * |
| 陈国中 等: "化痰行瘀汤对肝纤维化大鼠治疗作用及对脂质过氧化的影响研究", 《浙江中医药大学学报》 * |
| 陈国中 等: "化痰行瘀汤对肝纤维化大鼠血清肝功能及透明质酸含量的影响", 《浙江中医药大学学报》 * |
| 陈国中 等: "化痰行瘀汤抗大鼠肝纤维化作用机制研究", 《浙江中医药大学学报》 * |
| 陈国中 等: "化痰行瘀法治疗肝纤维化", 《实用中医内科杂志》 * |
| 陈国中 等: "肝纤维化中医病机与治疗的探讨", 《浙江中医杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
| CN105343625A (en) | Taraxacum oral liquid for expelling toxin, dehumidifying and benefiting gallbladder and preparation method thereof | |
| CN103041208B (en) | Chinese herbal preparation for treating climacteric syndrome of women, and preparation method thereof | |
| CN104305205B (en) | A kind of Semen Cuscutae oral liquid improving immunity and preparation method thereof | |
| CN105497816A (en) | Traditional Chinese medicine preparation for treating atherosclerosis and preparation method thereof | |
| CN102988733A (en) | Traditional Chinese medicine composition for treating postpartum hypogalactia and preparation method thereof | |
| CN105194421A (en) | Self-heal health-care oral solution capable of reducing blood fat and preparation method thereof | |
| CN104840695A (en) | Medicine combination for treating white scour of piglet and preparation method thereof | |
| CN105435197A (en) | Pharmaceutical composition for treating chronic lymphocytic thyroiditis and preparation method thereof | |
| CN104644967A (en) | Pharmaceutical composition for treating I-type diabetes and application thereof | |
| CN104042925A (en) | Traditional Chinese medicinal composition for treating gout and preparation method thereof | |
| CN103920011A (en) | Pharmaceutical composition for postpartum liver depression qi stagnation type hypogalactia and preparing method thereof | |
| CN112057590A (en) | Chinese medicinal preparation for treating hepatic fibrosis and preparation method thereof | |
| CN105169278A (en) | Dandelion oral liquid capable of protecting liver and benefiting gallbladder and preparation method thereof | |
| CN104083548A (en) | Traditional Chinese medicinal composition for treating ovarian cyst and preparation method thereof | |
| CN111084878A (en) | Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof | |
| CN110193076A (en) | A kind of Chinese medicine composition and preparation for treating hypertension, hyperlipidemia, high blood viscosity | |
| CN104689252A (en) | Traditional Chinese preparation for treating Wegener granulomatosis and preparation method thereof | |
| CN104435962A (en) | Pharmaceutical composition for treating dyspeptic diarrhea of piglets and preparation method thereof | |
| CN105169277A (en) | Fructus gardeniae oral liquid capable of protecting liver and benefiting gallbladder and preparation method thereof | |
| CN106110204A (en) | A kind of Herba Taraxaci oral liquid improving immunity and preparation method thereof | |
| CN105412673A (en) | Drug for treating Hashimoto disease and preparing method thereof | |
| CN105056160A (en) | Medicine composition for treating agalactia of cows and preparation method thereof | |
| CN105288166A (en) | Traditional Chinese medicine composition for thyroid enlargement and preparation method thereof | |
| CN105169275A (en) | Rheum officinale oral liquid capable of protecting liver and benefiting gallbladder and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201211 |
|
| RJ01 | Rejection of invention patent application after publication |